
The European Commission has granted marketing authorisation for Shire’s Intuniv for the treatment of ADHD in children. Intuniv (guanfacine hydrochloride prolonged …

Shire has posted strong growth in its full-year results, showing that the company is faring well even after the collapse …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

